Co-Authors
This is a "connection" page, showing publications co-authored by Patrick Johnson and Jonathon Senefeld.
Connection Strength
0.821
-
Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021 08; 61(8):2503-2511.
Score: 0.237
-
SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods. J Clin Microbiol. 2021 08 18; 59(9):e0123121.
Score: 0.060
-
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat Commun. 2021 08 11; 12(1):4864.
Score: 0.060
-
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021 08 09; 39(8):1031-1033.
Score: 0.060
-
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne). 2021; 8:684151.
Score: 0.059
-
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021 06 04; 10.
Score: 0.059
-
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 05; 96(5):1262-1275.
Score: 0.058
-
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021 03 18; 384(11):1015-1027.
Score: 0.058
-
In Reply - Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma. Mayo Clin Proc. 2021 01; 96(1):259-261.
Score: 0.057
-
Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020 09 01; 130(9):4791-4797.
Score: 0.056
-
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020 09; 95(9):1888-1897.
Score: 0.056